Angle begins liquid-biopsy Clinical Trials

Angle has begun clinical trials for their liquid biopsy technology, known as the Parsortix system. In cancer clinical trials, monitoring tumors to see if the drug being tested is effective often requires fresh tissue biopsies which are invasive in nature. Biomarker-driven cancer clinical studies continue to rise in popularity, leading companies like Angle to seek more patient-friendly and repeatable methods of disease and treatment monitoring.


The Parsortix system is a cell separation technology which enables a simple blood test to deliver the cells of interest in a manner appropriate for several types of downstream analyses. The technology is based around a microfluidic device which identifies and captures cells after determining their size and compressibility.


The system is able to capture all types of intact circulating tumor cells (CTCs), which enables a more complete idea of the cancer to be seen. It also allows for the analysis of DNA, RNA, and proteins, and can hopefully provide equivalent analysis to the more invasive tissue biopsy.


Given the more patient-friendly approach of a liquid biopsy, this kind of CTC analysis can be carried out repeatedly. This makes it an ideal method for longitudinal monitoring, particularly in the case of cancer as these diseases change and develop over time.


Furthermore, Parsortix may enable researchers to harvest and culture live CTCs for study outside of the body, including clinical research of drug efficacy outside of patients' bodies.


The clinical trial company has set out on a Phase III contract, and told Clinical trials Arena that they had already enrolled a “number” of patients and will carry out testing with the Parsortix system at various stages in the clinical protocol.


Want to learn more?

In addition to reporting clinical trial news and stories from within the patient community, we operate Citrus, a fully integrated recruitment and retention software. Citrus fits any clinical trial and simplifies the implementation of patient engagement in your clinical trial. Whether you are already working with CTMS systems or not, Citrus is the perfect add-on to make patient interaction effective.

Since 2015, our team has been hard at work raising awareness of clinical trials across the globe. A Forbes ‘30 Under 30’ company and a graduate of the renowned Techstar program in New York, Citruslabs is at the forefront of patient recruitment and retention technologies. With over 3 million patients now recorded on our databases, our patient recruitment dashboard is fast becoming the most efficient method of trial recruitment.

Now a #1 health app in 17 countries, our Mindmate app is helping to revolutionize the way we think about healthcare. Mindmate “[takes] senior care into the digital age” (Forbes, 2018) by providing people with the cognitive decline the essential tools to help them rebuild and maintain strong mental health. Trusted by millions of users, our health community continues to grow as the content available expands to the needs of individuals today.

With more than 200 research sites now using the Citrus platform to screen thousands of patients every month, researchers are now well on their way to finding new treatments for hundreds of different health conditions - something that just would not be possible without a technological solution. Make sure that your clinical trial is in the lucky 12% and turn that luck into guaranteed results with Citrus.


Check out what our customers have to say about us here.

And If you’d like to know more about how Citruslabs can help you recruit more effectively, get in touch with our team here.